Testing rifaximin to lower platelet reactivity in heart attack patients on ticagrelor
Tests rifaximin, an antibiotic, in adults after acute coronary syndrome taking ticagrelor.
Plain-language title generated from the registry record
Registry title: Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
Key facts
- Where
- Bydgoszcz, PolandSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07203846, who can take part
Where in Poland
- Cardiology Department, Dr. A. Jurasz University HospitalBydgoszcz, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Collegium Medicum w Bydgoszczy
- Trial code
- NCT07203846
- Record updated
- 2 October 2025
- Original description
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.Read full original descriptionShow less
Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.
Inclusion: Between 18 and 80 years of age; History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion; Current treatment with ticagrelor (90 mg orally twice a day); High platelet reactivity assessed with multiple electrode aggregometry method (AUC of >46 U); Provision of informed consent prior to any study procedures.
Exclusion: Ongoing treatment with rifamycins; Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion; Infection, including gastrointestinal infection, within a month prior to study inclusion; Current use of specific medications (warfarin, glycoprotein IIb/IIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents); History of hypersensitivity to rifaximin or other rifamycin-derived agent; History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor; History of Clostridium difficile infection; Platelet count < 100×10\^9/L or > 450×10\^9/L; Impaired liver function classified as Child-Pugh class B or C; Hemodynamic instability; Pregnancy or breastfeeding; Patients considered by the investigator to be uncooperative.